Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

NCT07569653 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Infections
Cytomegalovirus Disease
Hematopoietic Stem Cell Transplantation
Graft vs Host Disease

Interventions

DRUG: CMV-Specific T-cell Guided Letermovir Discontinuation
DRUG: Standard Letermovir Prophylaxis

Sponsor

WeiShi